IGF2 produced by CAFs binds to the IGF1 receptor in lung cancer cells and activates the AKT/Sox2 pathway, leading to increased expression of P-glycoprotein, which can pump out chemotherapeutic agents reaching the tumor. The gene discussed is AKT1; the disease is lung cancer.